inS3-54-A26

CAS No. 328998-77-2

inS3-54-A26 ( —— )

Catalog No. M27885 CAS No. 328998-77-2

inS3-54-A26, a novel inhibitor of the DNA-binding domain (DBD) of STAT3, suppresses tumor growth, metastasis and STAT3 target gene expression in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 264 Get Quote
5MG 402 Get Quote
10MG 593 Get Quote
25MG 888 Get Quote
50MG 1242 Get Quote
100MG 1701 Get Quote
500MG 3411 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    inS3-54-A26
  • Note
    Research use only, not for human use.
  • Brief Description
    inS3-54-A26, a novel inhibitor of the DNA-binding domain (DBD) of STAT3, suppresses tumor growth, metastasis and STAT3 target gene expression in vivo.
  • Description
    inS3-54-A26, a novel inhibitor of the DNA-binding domain (DBD) of STAT3, suppresses tumor growth, metastasis and STAT3 target gene expression in vivo.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ERβ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    328998-77-2
  • Formula Weight
    414.9
  • Molecular Formula
    C25H19ClN2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(=O)Nc1ccc(cc1)N1C(=O)\C(=C/c2ccc(Cl)cc2)C=C1c1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yang X, et al. Total Synthesis of (+)-Medicarpin. J Nat Prod. 2017 Dec 22;80(12):3284-3288.
molnova catalog
related products
  • 8-CHLOROQUINAZOLIN-4...

    8-CHLOROQUINAZOLIN-4(1H)-ONE is inhibitor of Poly [ADP-ribose] polymerase 1 (human).

  • Flecainide hydrochlo...

    Flecainide is a medication used to prevent and treat abnormally fast heart rates.?This includes ventricular and supraventricular tachycardias.

  • 3-Epiursolic acid

    3-Epiursolic acid may have antiinflammatory activity, it shows inhibition on Cathepsins L (catL), the IC50 value of 6.5 μM, cathepsins L (catL) and B play an important role in tumor progression and have been considered promising therapeutic targets in the development of novel anticancer agents.